These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 31026613)

  • 1. Cancer-selective nanoparticles for combinatorial siRNA delivery to primary human GBM in vitro and in vivo.
    Kozielski KL; Ruiz-Valls A; Tzeng SY; Guerrero-Cázares H; Rui Y; Li Y; Vaughan HJ; Gionet-Gonzales M; Vantucci C; Kim J; Schiapparelli P; Al-Kharboosh R; Quiñones-Hinojosa A; Green JJ
    Biomaterials; 2019 Jul; 209():79-87. PubMed ID: 31026613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subtle changes to polymer structure and degradation mechanism enable highly effective nanoparticles for siRNA and DNA delivery to human brain cancer.
    Tzeng SY; Green JJ
    Adv Healthc Mater; 2013 Mar; 2(3):468-80. PubMed ID: 23184674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of siRNA-loaded chitosan nanoparticles targeting Galectin-1 for the treatment of glioblastoma multiforme via intranasal administration.
    Van Woensel M; Wauthoz N; Rosière R; Mathieu V; Kiss R; Lefranc F; Steelant B; Dilissen E; Van Gool SW; Mathivet T; Gerhardt H; Amighi K; De Vleeschouwer S
    J Control Release; 2016 Apr; 227():71-81. PubMed ID: 26902800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Small interfering RNA (siRNA) to target genes and molecular pathways in glioblastoma therapy: Current status with an emphasis on delivery systems.
    Mirzaei S; Mahabady MK; Zabolian A; Abbaspour A; Fallahzadeh P; Noori M; Hashemi F; Hushmandi K; Daneshi S; Kumar AP; Aref AR; Samarghandian S; Makvandi P; Khan H; Hamblin MR; Ashrafizadeh M; Zarrabi A
    Life Sci; 2021 Jun; 275():119368. PubMed ID: 33741417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanoparticle-mediated knockdown of DNA repair sensitizes cells to radiotherapy and extends survival in a genetic mouse model of glioblastoma.
    Kievit FM; Wang K; Ozawa T; Tarudji AW; Silber JR; Holland EC; Ellenbogen RG; Zhang M
    Nanomedicine; 2017 Oct; 13(7):2131-2139. PubMed ID: 28614736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nasal Administration of Cationic Nanoemulsions as CD73-siRNA Delivery System for Glioblastoma Treatment: a New Therapeutical Approach.
    Azambuja JH; Schuh RS; Michels LR; Gelsleichter NE; Beckenkamp LR; Iser IC; Lenz GS; de Oliveira FH; Venturin G; Greggio S; daCosta JC; Wink MR; Sevigny J; Stefani MA; Battastini AMO; Teixeira HF; Braganhol E
    Mol Neurobiol; 2020 Feb; 57(2):635-649. PubMed ID: 31407144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RNA interference-mediated gene silencing of pleiotrophin through polyethylenimine-complexed small interfering RNAs in vivo exerts antitumoral effects in glioblastoma xenografts.
    Grzelinski M; Urban-Klein B; Martens T; Lamszus K; Bakowsky U; Höbel S; Czubayko F; Aigner A
    Hum Gene Ther; 2006 Jul; 17(7):751-66. PubMed ID: 16839274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of in vivo synthetic lethal RNAi responses to treat glioblastoma.
    Michiue H; Eguchi A; Scadeng M; Dowdy SF
    Cancer Biol Ther; 2009 Dec; 8(23):2306-13. PubMed ID: 19901546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delivery of siRNA in vitro and in vivo using PEI-capped porous silicon nanoparticles to silence MRP1 and inhibit proliferation in glioblastoma.
    Tong WY; Alnakhli M; Bhardwaj R; Apostolou S; Sinha S; Fraser C; Kuchel T; Kuss B; Voelcker NH
    J Nanobiotechnology; 2018 Apr; 16(1):38. PubMed ID: 29653579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RNA nanoparticle as a vector for targeted siRNA delivery into glioblastoma mouse model.
    Lee TJ; Haque F; Shu D; Yoo JY; Li H; Yokel RA; Horbinski C; Kim TH; Kim SH; Kwon CH; Nakano I; Kaur B; Guo P; Croce CM
    Oncotarget; 2015 Jun; 6(17):14766-76. PubMed ID: 25885522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A tumor-targeting cRGD-EGFR siRNA conjugate and its anti-tumor effect on glioblastoma in vitro and in vivo.
    He S; Cen B; Liao L; Wang Z; Qin Y; Wu Z; Liao W; Zhang Z; Ji A
    Drug Deliv; 2017 Nov; 24(1):471-481. PubMed ID: 28181832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ShRNA-based POLD2 expression knockdown sensitizes glioblastoma to DNA-Damaging therapeutics.
    Xu Q; Hu C; Zhu Y; Wang K; Lal B; Li L; Tang J; Wei S; Huang G; Xia S; Lv S; Laterra J; Jiang Y; Li Y
    Cancer Lett; 2020 Jul; 482():126-135. PubMed ID: 31954770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brain tumor-targeted therapy by systemic delivery of siRNA with Transferrin receptor-mediated core-shell nanoparticles.
    Wei L; Guo XY; Yang T; Yu MZ; Chen DW; Wang JC
    Int J Pharm; 2016 Aug; 510(1):394-405. PubMed ID: 27374198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PEI-Coated Fe₃O₄ Nanoparticles Enable Efficient Delivery of Therapeutic siRNA Targeting REST into Glioblastoma Cells.
    Wang R; Degirmenci V; Xin H; Li Y; Wang L; Chen J; Hu X; Zhang D
    Int J Mol Sci; 2018 Jul; 19(8):. PubMed ID: 30065155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polymeric nanoparticle mediated inhibition of miR-21 with enhanced miR-124 expression for combinatorial glioblastoma therapy.
    Liu Y; Zheng M; Jiao M; Yan C; Xu S; Du Q; Morsch M; Yin J; Shi B
    Biomaterials; 2021 Sep; 276():121036. PubMed ID: 34329919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brain Targeted Gold Liposomes Improve RNAi Delivery for Glioblastoma.
    Grafals-Ruiz N; Rios-Vicil CI; Lozada-Delgado EL; Quiñones-Díaz BI; Noriega-Rivera RA; Martínez-Zayas G; Santana-Rivera Y; Santiago-Sánchez GS; Valiyeva F; Vivas-Mejía PE
    Int J Nanomedicine; 2020; 15():2809-2828. PubMed ID: 32368056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular Targets and Nanoparticulate Systems Designed for the Improved Therapeutic Intervention in Glioblastoma Multiforme.
    Akhter MH; Rizwanullah M; Ahmad J; Amin S; Ahmad MZ; Minhaj MA; Mujtaba MA; Ali J
    Drug Res (Stuttg); 2021 Mar; 71(3):122-137. PubMed ID: 33167048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RNA interference for glioblastoma therapy: Innovation ladder from the bench to clinical trials.
    Lozada-Delgado EL; Grafals-Ruiz N; Vivas-Mejía PE
    Life Sci; 2017 Nov; 188():26-36. PubMed ID: 28864225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enabling Combinatorial siRNA Delivery against Apoptosis-Related Proteins with Linoleic Acid and α-Linoleic Acid Substituted Low Molecular Weight Polyethylenimines.
    Plianwong S; Thapa B; Kc RB; Kucharski C; Rojanarata T; Uludağ H
    Pharm Res; 2020 Feb; 37(3):46. PubMed ID: 32016611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. VDAC1 is a molecular target in glioblastoma, with its depletion leading to reprogrammed metabolism and reversed oncogenic properties.
    Arif T; Krelin Y; Nakdimon I; Benharroch D; Paul A; Dadon-Klein D; Shoshan-Barmatz V
    Neuro Oncol; 2017 Jul; 19(7):951-964. PubMed ID: 28339833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.